PP027—Drug-induced liver injury detected through a pharmacovigilance program based in laboratory signals

Drug-induced liver injury (DILI) is the most frequent reason for withdrawal of approved drugs from the market and accounts for 7% to 15% of the cases of acute liver failure in Europe and the United States. The risk of developing hepatotoxicity involves a complex interplay between the chemical properties of the drug, environment factors, age, sex, underlying diseases, and genetic factors.